CBCC Global Research
Mark Kirschbaum currently serves as the Chief Medical Officer at CBCC Global Research since November 2024 and is the Founder and President of Midtown Biopharma Consulting, LLC since August 2024. Previously, Mark held the position of Chief Medical Officer at Cyclacel Pharmaceuticals, Inc. from October 2020 to February 2024, and served as VP at ArQule from October 2019 to October 2020. Mark also worked as Senior Medical Director at Daiichi Sankyo, Inc. from March 2019 to October 2020. Mark's academic background includes education from the University of Washington and Yeshiva University.
This person is not in any teams
This person is not in any offices
CBCC Global Research
CBCC Global Research is a full service clinical contract research organization serving a wide spectrum of clinical research services including Phase II-IV clinical trials services, medical writing, Data Management, regulatory services, post marketing registry trials to the Bio-Pharmaceutical, Medical device, and Diagnostics companies. Our close association with our medical advisory board and research communities helps us decode the intricacies of clinical trials targeted at specific therapeutic areas. We have been offering a broad spectrum of clinical trial services in different therapeutic segments with a strong focus on oncology, neuropsychiatry, ophthalmology, and medical devices. CBCC Global Research, with 30+ years of Clinical research experience, has partnered with more than 30 innovator biopharmaceutical companies for over 150 clinical trial projects. Behind everything we do at CBCC is a focus on quality of service delivered, achieved through continued training and development of our people.